Every Form 4 that Kairos Pharma, Ltd. (KAPA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KAPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KAPA filings page.
Kairos Pharma, Ltd. reported an insider equity grant to its Chief Scientific Officer. On October 8, 2025, the officer acquired 171,756 restricted stock units (RSUs) of common stock at a price of $0.00 per share under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan.
The 171,756 RSUs are scheduled to vest on the first anniversary of the grant date, October 8, 2026. After this grant, the reporting person beneficially owns 1,311,739 shares, consisting of 1,135,317 shares of common stock and 176,422 RSUs that remain subject to vesting, all held as a direct ownership position.
Kairos Pharma, Ltd. director Hyun W. Bae reported equity awards and updated share ownership. On 09/16/2025, 10,000 restricted stock units (RSUs) of common stock were acquired at a price of $0.00, reflecting RSUs granted on September 16, 2024 in conjunction with the company’s initial public offering and scheduled to vest in three annual installments starting on the IPO anniversary. On 10/08/2025, an additional 19,084 RSUs were acquired at $0.00, which are scheduled to vest in full on the first anniversary of their grant date.
After these transactions, Bae beneficially owns 73,370 shares of common stock, consisting of 54,286 shares and 19,084 RSUs that remain subject to vesting, all held directly.
Kairos Pharma, Ltd. (KAPA) reported an equity award to its VP of Research and Development on a Form 4. On 10/08/2025, the officer acquired 152,672 restricted stock units (RSUs) of common stock at a price of $0.00 under the company’s 2023 Equity Incentive Plan. These RSUs are scheduled to vest in full on the first anniversary of the grant date.
Following this grant, the officer beneficially owns 299,529 equity interests, consisting of 142,191 shares of common stock and 157,338 RSUs that remain subject to vesting. The filing indicates the holdings are owned directly.
Kairos Pharma, Ltd. (KAPA) reported equity awards to a director via a Form 4 filing. On 09/16/2025, the director acquired 10,000 shares of common stock at $0.00 per share, representing restricted stock units (RSUs) granted under the company’s 2023 Equity Incentive Plan in connection with its initial public offering. Following this grant, the director beneficially owned 10,000 shares, combining common stock and unvested RSUs.
On 10/08/2025, the director received an additional 19,084 RSUs at $0.00 per share under the same plan, which are scheduled to vest in full on the first anniversary of the grant date. After this transaction, the director beneficially owned 29,084 shares, consisting of 3,334 shares of common stock and 25,750 RSUs that remain subject to vesting.
Kairos Pharma, Ltd. (KAPA) reported an insider equity award on a Form 4. Director Rahul Singhvi received 19,084 restricted stock units (RSUs) of common stock on 10/08/2025 under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. These 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date and were recorded at a price of $0.00, reflecting that this is an equity award, not an open-market purchase.
Following this grant, Singhvi beneficially owns 49,204 RSUs, all of which remain subject to vesting conditions and are reported as directly held. The filing is made by a single reporting person in the capacity of director, and it documents non-derivative equity compensation rather than any sale of shares.
Kairos Pharma (KAPA) reported an equity award to its Chief Financial Officer, Doug Samuelson. On 10/08/2025, he received 152,672 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan at a price of $0.00 per share. These RSUs are scheduled to vest in full on the first anniversary of the grant date.
Following this grant, Samuelson beneficially owns 293,039 common shares and RSUs in total, consisting of 140,367 shares of common stock and 152,672 RSUs that remain subject to vesting, all held in direct ownership.
Kairos Pharma (KAPA) reported an insider equity grant to its CEO and Chairman, John S. Yu, who is also a director and 10% owner. On 10/08/2025, he received 190,840 restricted stock units (RSUs) of common stock under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan, with all 190,840 RSUs scheduled to vest on the first anniversary of the grant date. Following this award, he directly beneficially owns 230,105 shares of common stock, which consist of 34,599 shares and 195,506 RSUs that remain subject to vesting, and indirectly holds 5,316,572 shares through The Yu Family Trust, where he is trustee. This filing reflects equity-based compensation and confirms his significant ongoing ownership stake.